Related references
Note: Only part of the references are listed.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009
D. E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2010)
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
E. C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Golimumab inpatients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Josef S. Smolen et al.
LANCET (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy
E. Keystone et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Rheumatoid arthritis - Strategies in the management of patients showing an inadequate response to TNF alpha antagonists
Joseph R. Lutt et al.
DRUGS (2008)
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug
K. L. Hyrich et al.
RHEUMATOLOGY (2008)
Treatment response to a second or third TNF-inhibitor in RA:: results from the South Swedish Arthritis Treatment Group Register
J. A. Karisson et al.
RHEUMATOLOGY (2008)
Delay in imaging versus clinical response: A rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis
Richard J. Wakefield et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
D. van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2007)
New therapies for treatment of rheumatoid arthritis
Josef S. Smolen et al.
LANCET (2007)
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice
W. Kievit et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
S. Bombardieri et al.
RHEUMATOLOGY (2007)
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
Daniel E. Furst et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders
M. H. Buch et al.
RHEUMATOLOGY (2007)
Cytokines in the pathogenesis of rheumatoid arthritis
Iain B. McInnes et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis - Results from a large UK national cohort study
Kimme L. Hyrich et al.
ARTHRITIS AND RHEUMATISM (2007)
Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists
Khalid M. Kamal et al.
JOINT BONE SPINE (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
A. Finckh et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
FC Breedveld et al.
ARTHRITIS AND RHEUMATISM (2006)
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
JJ Gomez-Reino et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Anti-TNF-α therapies:: they are all the same (aren't they?)
S Mpofu et al.
RHEUMATOLOGY (2005)
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal - Results from a twelve-month randomized, double-blind, placebo-controlled trial
MA Quinn et al.
ARTHRITIS AND RHEUMATISM (2005)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial
EC Keystone et al.
ARTHRITIS AND RHEUMATISM (2004)
Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor α blockade
MH Buch et al.
ARTHRITIS AND RHEUMATISM (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Measuring effectiveness of drugs in observational databanks: promises and perils
E Krishnan et al.
ARTHRITIS RESEARCH & THERAPY (2004)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial
EHS Choy et al.
ARTHRITIS AND RHEUMATISM (2002)
Infliximab and methotrexate in the treatment of rheumatoid arthritis
PE Lipsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)